In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure...
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associate...
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of...
On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent...
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends...
The Society for Integrative Oncology (SIO) and ASCO have partnered to develop a new guideline on integrative oncology care of symptoms of anxiety and depression in adults with cancer. The guideline reviews the evidence for a range of integrative approaches, including mindfulness-based...
Data from the phase III PSMAfore trial were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA13). Results showed that the trial of lutetium Lu-177 vipivotide tetraxetan met its primary endpoint, with a clinically meaningful and ...
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals in the discovery and development of trastuzumab—the first monoclonal antibody used against an oncogene that altered our entire approach...
In a collaborative study from the University of Freiburg and Stanford University reported in the Journal of Clinical Oncology, Jurik A. Mutter, BSc, of the Faculty of Medicine, University of Freiburg, and colleagues found that circulating tumor DNA (ctDNA) identified prior to and during treatment ...
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel may be a cost-effective second-line treatment option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Choe et al in Blood Advances. Background In...
For the treatment of advanced melanoma that is refractory to anti–PD-1 antibodies, there is no standard approach. The various options, with a look to the future, were discussed by Melinda L. Yushak, MD, MPH, Assistant Professor of Hematology and Oncology at Emory University School of Medicine, at...
In the phase II AMEERA-3 trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that the selective estrogen receptor degrader amcenestrant did not improve progression-free survival vs physician’s choice of endocrine therapy in patients with estrogen...